Understand the source comparison
Comparison at a glance
PT-141 (bremelanotide) Low sexual desire and related distress in premenopausal women (HSDD); erectile response in men Strong human clinical — FDA-approved for one specific indication Effect size is modest; approved only for premenopausal women with HSDD; nause
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (bremelanotide)
- Low sexual desire and related distress in premenopausal women (HSDD); erectile response in men
- Strong human clinical — FDA-approved for one specific indication
- Effect size is modest; approved only for premenopausal women with HSDD; nausea/flushing common
- Kisspeptin
- Sexual brain processing, arousal and penile tumescence in men and women with low desire
- Early human clinical — small, mechanistic proof-of-concept trials
- Tiny single-centre studies using IV infusion; no approved product; long-term efficacy unproven
- Melanotan II
- Initiating erections and raising sexual desire in men with erectile dysfunction
- Limited older human data — small trials, largely superseded by PT-141
- Very small samples; frequent nausea; unregulated, with separate safety concerns
- Oxytocin
- Orgasm intensity, contentment, partner bonding; vaginal/postmenopausal sexual function
- Mixed / weak human data
- Trials are inconsistent; benefits may not be on desire itself and can reflect other mechanisms